Biophytis S.A.

Regulatory Filings • Nov 9, 2016

Press release

BIOPHYTIS to attend to Jefferies conference (London) and European Midcap event (Geneva)

Romainville, November 9, 2016, 6:00pm – BIOPHYTIS (Alternext Paris : ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, today announced that it will attend to the Jefferies 2016 London Healthcare Conference, and to the Geneva European Midcap Event 2016.

The Jefferies Healthcare Conference is being held on November 16-17, 2016, at the Waldorf Hilton in London. The event gathers over 300 participating companies dedicated to pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors.

The European Midcap Event is being held on November 30 & December 1st, 2016 at the Hotel Beau Rivage in Geneva. The event gathers 60 companies and 150 investors dedicated to life sciences.

****

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry agerelated macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS ; ISIN: FR0012816825).

For more information: http://www.biophytis.com

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.

BIOPHYTIS Stanislas VEILLET CEO contact@biophytis.com Tel : +33 (0) 1 41 83 66 00

Citigate Dewe Rogerson Laurence BAULT/Antoine DENRY Laurence.bault@citigate.fr/antoine.denry@citigate.fr Tel : +33 (0)1 53 32 84 78 Mob : +33(0)6 64 12 53 61

LifeSci Advisors Chris MAGGOS

Managing Director, Europe chris@lifesciadvisors.com Tel : +41 79 367 6254

Milestones Bruno ARABIAN barabian@milestones.fr Tel : +33 (0) 1 83 62 34 84 Mob : +33 (0) 6 87 88 47 26